Safety and Performance of the CG-100 in Patients Undergoing Colorectal Surgery.

Colospan is initiating a pivotal clinical prospective, multi-center, single-arm, open-label study designed to evaluate safety and performance profile of the CG-100 Intraluminal Bypass Device in patients undergoing colorectal surgery study.

Up to 137 patients (in total) will be enrolled in up to 12 sites in Europe, Israel and USA.

Study objectives Primary Objective: To evaluate the performance of the CG-100 Intraluminal Bypass Device, in reducing contact of fecal content with an anastomotic site in patients undergoing colorectal surgery (open, robotic, or laparoscopic) Secondary Objectives: To evaluate Performance in terms of clinical and radiological anastomotic leakage Successful positioning and maintenance of device position To assess the ease of the device's application and removal Safety: To assess the safety profile of the CG-100 Intraluminal Bypass Device.

Inclusion criteria

• The patient is willing to comply with protocol-specified follow-up evaluations
• Patient 22-75 years of age at screening
• The patient is scheduled to undergo an elective colorectal surgery (open, laparoscopic, or robotic) which will require the creation of an anastomosis, maximally 20 cm proximal from the anal verge
• The patient or legally authorized representative, has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB).

Exclusion criteria

Preoperative

• Pregnant or nursing female subjects. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to surgical procedure per site standard test.
• Patient surgical treatment is acute (not elective)
• Patient has local or systemic infection at the time of intervention (e.g., peritonitis)
• Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study
• Patients with ASA classification > 3
• Albumin < 30 g/liter
• Patient has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis or extensively spread inflammatory bowel disease
• BMI ≥ 40
• Subject is going through another surgical procedure (other than ileostomy or adhesiolysis) during the surgery.
• Patient is participating in another clinical trial within 30 days of screening
• Patient has been taking regular steroid medication in the last 6 months.
• Patient has contraindications to general anesthesia
• Patient has preexisting sphincter problems
• Patient has evidence of extensive local disease in the pelvis
• Any condition which in the opinion of the investigator may jeopardize the patient's safe participation Intraoperative (prior to device deployment)
• Anastomosis is located more than 20 cm from the anal verge
• Internal diameter lumen of the colon is smaller than 25 mm or larger than 34 mm
• Blood loss (> 500 cc)
• Anastomosis was not performed for any reason other than consequences as a result of use of the study device -